Treatment of Pulmonary Arterial Hypertension
Authors:
- Marc HumbertMarc Humbert
- Olivier SitbonOlivier Sitbon
- Gérald SimonneauGSGérald Simonneau
Top Cited Papers
- 30 September 2004
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (14) , 1425-1436
Abstract
Pulmonary arterial hypertension, which is characterized by vascular proliferation and remodeling of small pulmonary vessels, leads to a progressive increase in pulmonary vascular resistance and, ultimately, to right ventricular failure and death. Despite recent major improvements in therapy, no current treatments cure this devastating condition. This article discusses recent progress in developing treatments that prolong patients' lives and improve their quality of life.Keywords
This publication has 91 references indexed in Scilit:
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJACC, 2004
- Clinical classification of pulmonary hypertensionJACC, 2004
- Primary pulmonary hypertensionThe Lancet, 2003
- Therapy of Pulmonary Hypertension: The Evolution from Vasodilators to Antiproliferative AgentsAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJACC, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSIONClinics in Chest Medicine, 2001
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996